Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects

Pharmacology

Volumn 85, Issue 3, 2010, Pages 131-135

  Huang, Chen Ling ^a   Hsu, Chung Huei ^a,b   Huang, Kuo Cherh ^b   Su, Hsiu Yueh ^b   Weng, Shuen Fu ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Gastrin; Ghrelin; Insulin; Sitagliptin

Indexed keywords

GASTRIN; GHRELIN; GLUCOSE; INSULIN; SITAGLIPTIN;

ADULT; ARTICLE; BLOOD SAMPLING; DRUG EFFECT; FEMALE; GASTRIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GASTRINS; GHRELIN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; POSTPRANDIAL PERIOD; PYRAZINES; RADIOIMMUNOASSAY; TABLETS; TIME FACTORS; TRIAZOLES;

EID: 76049105515     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000280583     Document Type: Article

References (12)

1. Herman GA, Stevens C, Van Dyck K, et al: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl pep-tidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688.
2. Herman GA, Bergman A, Stevens C, et al: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619.
3. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-E206.
4. Drucker DJ: The role of gut hormones in glucose homeostasis. J Clin Invest 2007;177:24-32.
5. Meier JJ, Gallwitz B, Salmen S, et al: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-2725.
6. Van Der Lely AJ, Tschöp M, Heiman M, Ghigo E: Biological, physiological, pathophysiological, and pharmacological aspect of ghrelin. Endocr Rev 2004;25:426-457.
7. Gardiner J V, Jayasena CN, Bloom SR: Gut hormones: a weight off your mind. J Neuroendocrinol 2008;20:834-841.
8. Wren AM, Seal LJ, Cohen MA, et al: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5995.
9. Schubert ML: Gastric secretion. Curr Opin Gastroenterol 2008;24:659-664.
10. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-1719.
11. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML: Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-709.
12. Djurhuus CB, Hansen TK, Gravholt C, et al: Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm Metab Res 2002;34:411-413.